Reply
Yi‐Te Lee, Yazhen Zhu, Ju Dong Yang, Vatche G. Agopian, Hsian‐Rong Tseng – 10 August 2022
Reply
Laurens A. Kleef, Milan J. Sonneveld, Robert J. Knegt – 10 August 2022
Fibroblasts to hepatocytes: A nonstop flight into cell therapy for liver diseases?
Valerie Gouon‐Evans, Romina Fiorotto – 10 August 2022
Letter to the editor: Screening for fatty liver disease and fibrosis in the elderly population: A call for action
Jie Li, Mindie H. Nguyen – 10 August 2022
Reply
Laurens A. Kleef, Milan J. Sonneveld, Robert J. Knegt – 10 August 2022
Letter to the editor: Focus on metabolic dysfunction–associated fatty liver disease, even if patients have a history of excessive alcohol consumption
Shi‐Tao Jiang, Yi‐Yao Xu, Xin Lu – 10 August 2022
Intrahepatic paracrine signaling by cardiotrophin‐like cytokine factor 1 ameliorates diet‐induced NASH in mice
Tongyu Liu, Qiuyu Wang, Linkang Zhou, Peng Zhang, Lin Mi, Xiaoxue Qiu, Zhimin Chen, Henry Kuang, Siming Li, Jiandie D. Lin – 10 August 2022
Reply
Laurens A. Kleef, Robert J. Knegt, Willem Pieter Brouwer – 9 August 2022
Letter to the editor: Fatty liver and mortality in populations who are elderly
Yanrong Sun, Junwei Zhang, Hanfei Wang, Wenjuan Wang, Huiru Ding, Yiyao Xu, Lihua Qin – 9 August 2022
Sarcopenia, healthy living, and mortality in patients with chronic liver diseases
Catherine Van Dongen, James M. Paik, Michael Harring, Youssef Younossi, Jillian K. Price, Khaled Kabbara, Pegah Golabi, Zobair M. Younossi – 9 August 2022 – Chronic liver diseases (CLDs) are associated with increased morbidity and mortality. Sarcopenia is an important complication of CLD that can be impacted by several modifiable risk factors. Our aim was to assess the associations between healthy living, sarcopenia, and long‐term outcomes among patients with CLD. We used the Third National Health and Nutrition Examination Survey data with National Death Index–linked mortality files.